Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
Renal cell carcinoma accounts for roughly 3 % of all cancer. It is a rather aggressive cancer type, which means that patients who present with an advanced disease have a rather poor prognosis. When this study has been started the standard therapy for patients has been cytokines, which might be accompanied by significant toxicities or might fail the therapeutic goal. In these cases sorafenib can be a feasible therapeutic option. This non-interventional study has been created and is being conducted to collect clinical data on the patients' therapy with sorafenib in an everyday treatment schedule. The main goal of this study focuses on patient characteristics and tumor status in RCC treated with sorafenib as well as the treatment duration and safety of sorafenib under everyday treatment conditions.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Patients with diagnosis of advanced RCC and decision taken by the investigator to prescribe Sorafenib
Exclusion criteria
- Exclusion criteria must be read in conjunction with the local product information
Trial design
2,840 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal